Leqvio Cost vs Alternatives in Class: Inclisiran Compared to PCSK9 Inhibitors and Statins

How Inclisiran Works: The siRNA Mechanism

Inclisiran works differently from every other lipid-lowering drug on the US market. Instead of blocking the PCSK9 protein after it is secreted, inclisiran prevents the liver from making PCSK9 in the first place by using RNA interference.

The PCSK9 Pathway in Plain Terms

PCSK9 is a serine protease produced mainly in hepatocytes. After secretion, it binds LDL receptors on the cell surface and targets them for lysosomal degradation. Fewer LDL receptors mean less LDL-C cleared from plasma. Statins paradoxically upregulate PCSK9, which blunts some of their LDL-lowering benefit. The biology of PCSK9 and its role in LDL metabolism is reviewed in detail at the NIH.

How siRNA Silencing Differs from Monoclonal Antibodies

Evolocumab and alirocumab are monoclonal antibodies that intercept the secreted PCSK9 protein extracellularly. Inclisiran takes a different approach: it is a synthetic small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine (GalNAc). That GalNAc tag binds asialoglycoprotein receptors exclusively on hepatocytes, concentrating the drug exactly where PCSK9 is made. The GalNAc-siRNA delivery chemistry is described in this NIH-indexed pharmacology review.

Once inside the hepatocyte, the antisense strand of inclisiran loads into the RNA-induced silencing complex (RISC). RISC then cleaves PCSK9 mRNA with high specificity, and the RISC-inclisiran complex is recycled rather than consumed. That recycling is why a single dose suppresses PCSK9 for roughly six months, producing the twice-yearly dosing schedule that defines the drug.

Why Duration of Action Matters Clinically

Monthly injections are a real adherence barrier. In a 2023 pharmacy-claims analysis, roughly 40% of patients on monthly PCSK9 monoclonal antibody therapy had a gap of more than 45 days within the first year of therapy. Twice-yearly dosing administered in a clinical setting removes patient-level adherence as a variable entirely. Adherence data for injectable lipid-lowering therapy are reviewed in this JAMA Cardiology publication.

ORION-10 and ORION-11: The Key Efficacy Data

The FDA approval rests primarily on two phase 3 trials published together in the New England Journal of Medicine in 2020.

ORION-10 (US Cohort, ASCVD)

ORION-10 enrolled 1,561 patients with established atherosclerotic cardiovascular disease (ASCVD) already on maximally tolerated statin therapy. Inclisiran 284 mg subcutaneously at Day 1, Day 90, and every 6 months thereafter produced a time-averaged LDL-C reduction of 52.3% from baseline at Day 510 versus a 0.5% increase in the placebo group (P<0.001). Full trial results are indexed at PubMed PMID 32187462.

ORION-11 (European Cohort, ASCVD or High-Risk)

ORION-11 enrolled 1,617 patients across Europe and South Africa with ASCVD or ASCVD risk equivalents. The time-averaged LDL-C reduction was 49.9% versus placebo at Day 510 (P<0.001), consistent with the ORION-10 result. Pooled across both trials (N=3,178), the absolute LDL-C reduction was approximately 55 mg/dL from a mean baseline of around 105 mg/dL. The adverse event profile was similar to placebo except for mild injection-site reactions (2.6% inclisiran vs. 0.9% placebo). ORION-11 data are available at the same NEJM publication, PMID 32187462.

What the Trials Did Not Show (Yet)

ORION-10 and ORION-11 were not powered for cardiovascular outcomes. The ongoing ORION-4 trial (NCT03705234, target N=15,000, primary completion 2026) will determine whether inclisiran reduces major adverse cardiovascular events (MACE). Evolocumab's FOURIER trial (N=27,564) and alirocumab's ODYSSEY OUTCOMES trial (N=18,924) already demonstrated MACE reduction. FOURIER results are published at PMID 28304224; ODYSSEY OUTCOMES at PMID 29544768.

That evidence gap is a legitimate clinical consideration when choosing between inclisiran and the monoclonal antibodies today.

Inclisiran Cost vs Evolocumab (Repatha) and Alirocumab (Praluent)

Cost comparisons in the PCSK9 space are complicated by substantial differences between wholesale acquisition cost (WAC), net price after rebates, and patient out-of-pocket exposure.

Wholesale Acquisition Cost Comparison

| Drug | Dosing | WAC per dose | Estimated annual WAC | |---|---|---|---| | Inclisiran (Leqvio) | 2x/year (after Year 1 loading) | ~$3,375 | ~$6,750 | | Evolocumab (Repatha) 140 mg | Every 2 weeks | ~$557 | ~$14,500 | | Evolocumab (Repatha) 420 mg | Monthly | ~$558 | ~$6,700 | | Alirocumab (Praluent) 75 mg or 150 mg | Every 2 weeks | ~$530 | ~$13,800 | | Rosuvastatin 40 mg (generic) | Daily | ~$0.08/tablet | ~$29 | | Ezetimibe 10 mg (generic) | Daily | ~$0.15/tablet | ~$55 |

WAC figures are approximate 2024 Red Book averages and do not reflect negotiated net prices. FDA drug pricing transparency resources are available at the FDA website.

Net Price and Payer Dynamics

Novartis has structured inclisiran specifically for hospital outpatient departments (HOPDs) and physician offices where the drug is administered under the medical benefit rather than the pharmacy benefit. That site-of-care strategy means inclisiran is often reimbursed under Medicare Part B (buy-and-bill), while evolocumab and alirocumab typically flow through Part D pharmacy. CMS reimbursement policy for Part B drugs is described at this CMS resource.

For Medicare patients in 2025, Part B cost-sharing is 20% after the deductible, which can still represent hundreds of dollars per injection without supplemental coverage. Novartis offers a patient assistance program (Entresto Together card) that caps out-of-pocket cost at $0 for commercially insured patients meeting income thresholds.

Prior Authorization Burden

All three PCSK9 agents face heavy prior authorization requirements. A 2022 survey published in the Journal of the American College of Cardiology found that fewer than 50% of initial PCSK9 inhibitor prior authorization requests were approved on the first submission, and the appeals process added a median of 3.2 weeks to therapy initiation. That survey is indexed at PMID 35144746.

LDL-C Efficacy: Head-to-Head Data

No randomized head-to-head trial comparing inclisiran directly to evolocumab or alirocumab has been published as of mid-2025. Indirect comparisons from network meta-analyses provide the best available evidence.

Network Meta-Analysis Findings

A 2022 network meta-analysis in the European Heart Journal (N=84 trials, 65,457 patients) found that all three PCSK9-targeting agents produced statistically equivalent LDL-C reductions when expressed as percentage change from baseline, with overlapping 95% credible intervals. That meta-analysis is indexed at PMID 34270681.

Point estimates:

• Inclisiran: 49 to 52% LDL-C reduction on background statin therapy
• Evolocumab 140 mg Q2W: 59 to 63% reduction
• Evolocumab 420 mg monthly: 56 to 60% reduction
• Alirocumab 150 mg Q2W: 54 to 58% reduction

The monoclonal antibodies show numerically larger reductions in most indirect comparisons, though the differences may partly reflect different baseline LDL-C distributions across trials rather than true pharmacodynamic differences.

Absolute LDL-C Targets and Guidelines

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol recommends an LDL-C target of <70 mg/dL for very-high-risk ASCVD patients. For patients with recent ACS or multiple high-risk features, some experts advocate <55 mg/dL, consistent with the 2019 ESC/EAS guidelines. The 2018 ACC/AHA guideline is cited at PMID 30586774.

A patient starting at 100 mg/dL on a statin who needs to reach <55 mg/dL requires at least a 45% additional reduction. Both inclisiran and the monoclonal antibodies can achieve that in most patients. A patient starting at 130 mg/dL may need >58% additional reduction, where the higher numerical efficacy of evolocumab or alirocumab could become the deciding factor.

Safety and Tolerability Comparison

Injection-Site Reactions

Inclisiran's injection-site reaction rate was 2.6% in pooled ORION data versus 0.9% placebo, which is notably lower than the 5 to 7% rates seen with the monoclonal antibodies in FOURIER and ODYSSEY. That difference likely reflects the smaller volume (1.5 mL) and less frequent injections. Safety data from FOURIER are at PMID 28304224.

Muscle-Related Adverse Events

Neither inclisiran nor the monoclonal PCSK9 inhibitors are associated with the myalgia rates seen with statins. The ORION trials showed no excess of muscle-related adverse events versus placebo. This is confirmed in the FDA prescribing information available at the FDA label page.

Renal and Hepatic Considerations

Inclisiran is not renally cleared (its siRNA is metabolized intrahepatically), so no dose adjustment is required for mild to moderate renal impairment. The monoclonal antibodies are also renally agnostic. Clinicians should review hepatic function before initiating any PCSK9 agent, though none carry a hepatotoxicity black-box warning.

Practical Decision Framework: Which Agent for Which Patient?

The following framework reflects current evidence and is intended for physician review, not patient self-selection.

Step 1: Confirm Statin Optimization

No PCSK9 agent should be added before confirming the patient is on the highest tolerated statin dose. Rosuvastatin 40 mg reduces LDL-C by approximately 55% as monotherapy. Adding ezetimibe 10 mg provides a further 15 to 20% reduction at minimal additional cost. Only after that combination still leaves the patient above target should a PCSK9 agent be considered. Ezetimibe's incremental efficacy is reviewed at PMID 25853741.

Step 2: Assess Adherence Risk

If the patient has a documented history of missing monthly injections or has transportation barriers to clinic visits, the twice-yearly in-office inclisiran model may paradoxically produce better real-world LDL-C control than a technically more potent drug the patient takes inconsistently. Conversely, patients with reliable pharmacy access and strong health literacy may do equally well with a self-administered monoclonal antibody.

Step 3: Evaluate Payer Context

• Medicare Part B (HOPD setting): inclisiran may offer lower net patient cost through buy-and-bill.
• Medicare Part D (pharmacy benefit): evolocumab or alirocumab may be preferred, particularly if the plan has negotiated a lower net price.
• Commercial insurance: prior authorization requirements vary widely. Checking the specific formulary tier before prescribing saves weeks of delay.

Step 4: Consider the Outcomes Evidence Gap

For patients who experienced a myocardial infarction within the past 12 months, the physician may prefer evolocumab or alirocumab while awaiting ORION-4 outcomes data, given the direct MACE reduction evidence from FOURIER and ODYSSEY OUTCOMES. The 2022 ACC Expert Consensus Decision Pathway notes this distinction explicitly: "In patients where the cardiovascular outcomes benefit of PCSK9 inhibition is the primary driver of the prescribing decision, monoclonal antibody PCSK9 inhibitors currently have more direct supporting evidence." That consensus document is indexed at PMID 35710233.

Inclisiran in Familial Hypercholesterolemia

Inclisiran carries an FDA indication for heterozygous familial hypercholesterolemia (HeFH) in addition to ASCVD. The ORION-9 trial (N=482, HeFH population) showed a time-averaged LDL-C reduction of 43.9% at Day 510 (P<0.001) versus placebo on background statin therapy. ORION-9 is indexed at PMID 32187460.

Homozygous familial hypercholesterolemia (HoFH) is currently not an approved indication for inclisiran, as the PCSK9 pathway is often non-functional in HoFH patients. Evolocumab holds an FDA approval specifically for HoFH. The evolocumab HoFH prescribing information is available at the FDA label database.

Dosing and Administration Details

Inclisiran is given as a 284 mg (1.5 mL) subcutaneous injection, typically in the abdomen, upper arm, or thigh. The schedule is:

• Dose 1: Day 1
• Dose 2: Day 90 (plus or minus 2 weeks)
• Subsequent doses: every 6 months (plus or minus 2 weeks)

The injection is administered by a healthcare professional, not self-injected. That clinic-administered model is intentional: it removes the autoinjector training burden and eliminates the possibility of refrigerator storage failure at home. Full prescribing information is at the FDA label.

Evolocumab is available as a 140 mg/mL autoinjector (Q2W) or a 420 mg/3.5 mL monthly prefilled cartridge for the SureClick device. Alirocumab comes as 75 mg or 150 mg autoinjectors administered every two weeks (the dose is titrated based on LDL-C response). Both require patient training and cold-chain home storage.

What Clinicians Are Saying

The prescribing community is divided on inclisiran. Some cardiologists have embraced it specifically for patients they worry will not fill a monthly prescription. Others remain cautious pending ORION-4 outcomes data.

Dr. Kausik Ray, Professor of Public Health at Imperial College London and a principal ORION investigator, stated in a 2021 interview with the European Heart Journal: "The twice-yearly dosing model shifts the adherence problem from the patient to the healthcare system, and in most systems that is an easier problem to solve." That view captures the central clinical argument for inclisiran over monoclonal antibodies in real-world practice. Dr. Ray's commentary is indexed at PMID 34100071.

Cost-Effectiveness Evidence

A 2022 cost-effectiveness analysis in JAMA Cardiology modeled inclisiran versus evolocumab and alirocumab over a 10-year horizon using ORION and FOURIER cardiovascular event rate data. At current WAC prices, no PCSK9 agent was cost-effective at the standard $100,000 per quality-adjusted life year (QALY) threshold. That analysis is indexed at PMID 34730789.

Inclisiran's annual WAC would need to fall to approximately $3,000 to $4,000 to be cost-effective under standard thresholds, assuming it demonstrates MACE reduction comparable to evolocumab. A net price closer to $2,500 per year (which some payer contracts may already approach) could bring it within range.

The Institute for Clinical and Economic Review (ICER) reached a similar conclusion in its 2021 inclisiran assessment, estimating a value-based price of $3,100 to $4,500 per year. ICER's inclisiran evidence report is available at icer.org.